All Videos

Experts describe roflumilast patient selection for plaque psoriasis treatment.

Linda Stein Gold, MD, and Jennifer Soung, MD, discuss real world experience of using roflumilast for plaque psoriasis therapy.

Dr Joshua Zeichner reviews the mechanism of action of Isotretinoin and highlights utilization requirements in patients prescribed this treatment.

Joshua Zeichner, MD, shares his insight into some causes of acne and the utility of clascoterone cream 1% combat this condition.

An expert in acne management provide his opinion on the differences between generic vs brand acne treatments and shares his thoughts on the utilization of available isotretinoin formulations.

Aaron Farberg, M.D discusses some common acne causes, highlighting the role of stress, diet, and androgen receptors for this condition.

Dr Aaron Farberg shares his recommendations for discussing acne treatment options with patients and provides insight on setting and managing patients’ goals and expectations.

Jennifer Soung, MD, review long term data for tapinarof for the treatment of plaque psoriasis.

Experts in plaque psoriasis provide an overview of the itch response and tolerability profile of tapinarof.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses if telehealth is here to stay in dermatology.

Linda Stein Gold, MD, reviews phase III data for the topical agent tapinarof for the treatment of plaque psoriasis.

Linda Stein Gold, MD, and Jennifer Soung, MD, provides an overview of the safety profile and topical vehicle of roflumilast for the treatment of plaque psoriasis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, evaluate the effect of the rapidly changing therapeutic landscape in atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the burden of atopic dermatitis and discuss how they talk to patients about the impact their disease has on their lives.

Linda Stein Gold, MD, discusses the itch response of roflumilast for the treatment for plaque psoriasis.

Experts in plaque psoriasis discuss the primary endpoint data responses of roflumilast in the DERMIS-1/DERMIS-2 trials.

Dr Leon Kircik, comments on the impact the multiple formulations of isotretinoin had on acne care; and highlights the efficacy differences between generic vs brand formulations.

Leon Kircik, M.D., discusses the indication of isotretinoin for use in patients suffering from acne, highlighting the difference between high and low dose administration needs.

An expert in acne management shares her insight into the patient characteristics a provider needs to consider when assessing the risk/benefit of a therapeutic agent for the management of acne.

Dr Zoe Diana Draelos discusses the role of ancillary skin care products in the management of acne and stresses the importance of setting patient expectations.

Zoe Diana Draelos, MD comments on the importance of tailoring acne treatments based on disease severity and the ability to target key acne pathogenesis factors.

Jennifer Soung, MD, provides an overview of the phase III trials, DERMIS-1/DERMIS-2, in which roflumilast was used to treat plaque psoriasis

Linda Stein Gold, MD, and Jennifer Soung, MD, provide an overview of the different, evidence-based topical strategies for treating plaque psoriasis.

Nada Elbuluk, MD, and David Rosmarin, MD, provide advice to physicians on the management of vitiligo.

Nada Elbuluk, MD, and David Rosmarin, MD, share their thoughts on future treatments in the pipeline for vitiligo.

Drs Raj Chovatiya and Neal Bhatia summarize their final thoughts on the available treatment options for the management of atopic dermatitis.

Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.

Experts in dermatology discuss the use of oral and topical JAK inhibitors in clinical practice and their reflection of overarching treatment guidelines and indications.

Drs Raj Chovatiya and Neal Bhatia highlight the biological targets of current and emerging treatments for the management of atopic dermatitis and discuss the importance of safety and long-term data.

Raj Chovatiya, MD, PhD, and Neal Bhatia, MD, share their thoughts on the clinical implications of the rapid expansion of the atopic dermatitis treatment armamentarium.